Kurs & Likviditet
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
2022-12-09 18:32:06
Oslo, Norway, 9 December 2022
Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") today
announces an update following the Extraordinary General Meeting held on 1
December at which the proposed merger transaction with APIM Therapeutics AS
("APIM") did not obtain a sufficient majority of votes and was therefore voted
down.
A new Extraordinary General Meeting ("EGM") will be convened by the Board of
Directors with an agenda proposed by North Energy. North Energy is currently the
largest shareholder of Nordic Nanovector.
The current Board of Directors of Nordic Nanovector has decided to resign at the
upcoming EGM and not to stand for re-election at that meeting.
An invitation to this new EGM to elect both members of the Nomination Committee
and a new Board of Directors will be sent out at the start of next week.
Hans Peter Bøhn, as the only remaining member of the Nomination Committee, may
be contacted to propose new members of the Nomination Committee and new members
of the Board of Directors.
The Board and the company continue to further preserve cash resources and as a
result, Malene Brondberg, current interim Chief Executive Officer ("CEO") and
Chief Financial Officer ("CFO") will transition out of the Company. A search for
a new CEO is expected to commence immediately after a new Board of Directors of
Nordic Nanovector has been elected.
Chairman, Jan H. Egberts commented: "While the Board believed that the proposed
merger with APIM was in the best interests of all shareholders, we did not
receive the required level of shareholder support for this transaction.
Following this result, Malene Brondberg will end her role as interim CEO and CFO
and the current Board will not stand for re-election. I would like to extend the
Board's thanks to Malene for her support of the Company, particularly during the
recent and very difficult circumstances we have faced following the
disappointing results from the PARADIGME study for Betalutin® in third-line
Follicular Lymphoma".
Contacts
Malene Brondberg, Interim CEO and CFO of Nordic Nanovector
+ 44 7561 431 762
ir@nordicnanovector.com
International Media: Frazer Hall / Mark Swallow (MEDiSTRAVA Consulting)
+44 203 928 6900
nordicnanovector@medistrava.com
Media in Norway - Jan Lilleby / Stein Jacob Frisch (Lilleby Frisch)
+47 916 10 911
sjf@lillebyfrisch.no
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company's pipeline includes:
· Betalutin® and Humalutin®, both CD37-targeting radioimmunotherapies
incorporating the beta emitter lutetium-177 to treat non-Hodgkin's lymphoma
(NHL)